Hartford Funds Management Co LLC Buys 163 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Hartford Funds Management Co LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 34.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 630 shares of the medical research company’s stock after acquiring an additional 163 shares during the period. Thermo Fisher Scientific makes up about 0.0% of Hartford Funds Management Co LLC’s holdings, making the stock its 14th largest position. Hartford Funds Management Co LLC’s holdings in Thermo Fisher Scientific were worth $319,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 2.7% during the 2nd quarter. Opal Wealth Advisors LLC now owns 643 shares of the medical research company’s stock valued at $349,000 after buying an additional 17 shares during the period. Fortitude Advisory Group L.L.C. increased its position in shares of Thermo Fisher Scientific by 1.8% during the 2nd quarter. Fortitude Advisory Group L.L.C. now owns 987 shares of the medical research company’s stock worth $536,000 after purchasing an additional 17 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its stake in Thermo Fisher Scientific by 11.9% during the second quarter. Creative Financial Designs Inc. ADV now owns 169 shares of the medical research company’s stock worth $92,000 after buying an additional 18 shares during the period. Tradition Wealth Management LLC increased its stake in Thermo Fisher Scientific by 2.2% during the second quarter. Tradition Wealth Management LLC now owns 837 shares of the medical research company’s stock worth $455,000 after purchasing an additional 18 shares during the period. Finally, Hemington Wealth Management increased its stake in Thermo Fisher Scientific by 3.9% during the 2nd quarter. Hemington Wealth Management now owns 506 shares of the medical research company’s stock worth $275,000 after buying an additional 19 shares during the period. 85.92% of the stock is owned by institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 8,200 shares of the stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total value of $3,997,090.00. Following the completion of the transaction, the chief executive officer now owns 178,005 shares in the company, valued at $86,768,537.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 31st. The stock was sold at an average price of $509.97, for a total transaction of $5,099,700.00. Following the sale, the chief executive officer now owns 178,005 shares in the company, valued at $90,777,209.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 8,200 shares of the firm’s stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $487.45, for a total value of $3,997,090.00. Following the completion of the transaction, the chief executive officer now directly owns 178,005 shares in the company, valued at $86,768,537.25. The disclosure for this sale can be found here. Insiders sold 31,475 shares of company stock valued at $16,073,443 in the last three months. 0.43% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO traded down $13.34 on Wednesday, hitting $567.38. 426,611 shares of the company traded hands, compared to its average volume of 1,952,851. The company has a 50 day moving average of $556.73 and a 200-day moving average of $547.95. Thermo Fisher Scientific Inc. has a 12-month low of $475.77 and a 12-month high of $618.35. The stock has a market capitalization of $222.52 billion, a PE ratio of 32.64, a PEG ratio of 2.11 and a beta of 0.83. The company has a quick ratio of 1.22, a current ratio of 1.74 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last posted its quarterly earnings data on Wednesday, October 26th. The medical research company reported $5.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.30. Thermo Fisher Scientific had a net margin of 15.92% and a return on equity of 22.97%. The firm had revenue of $10.68 billion for the quarter, compared to analyst estimates of $9.86 billion. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.04 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase plan on Thursday, November 10th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 16th. Shareholders of record on Thursday, December 15th were issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date of this dividend was Wednesday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.75%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. SVB Leerink increased their price objective on Thermo Fisher Scientific from $555.00 to $620.00 and gave the company an “outperform” rating in a research note on Friday, January 6th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $711.00 to $696.00 and set an “outperform” rating on the stock in a research note on Thursday, October 27th. Citigroup dropped their price objective on shares of Thermo Fisher Scientific from $715.00 to $650.00 and set a “buy” rating on the stock in a research report on Thursday, October 27th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating for the company in a research report on Tuesday, January 3rd. Finally, Benchmark cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Thursday, October 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $633.30.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.